Assessment of mouse VEGF neutralization by ranibizumab and aflibercept. [PDF]
PLoS ONE, 2022 PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro.MethodsIn vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced ...
Yusuke Ichiyama +7 more
doaj +3 more sources
Short-Term Intraocular Pressure Changes After Intravitreal Aflibercept 8 mg via Prefilled Syringe [PDF]
Ophthalmology and TherapyIntroduction Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is a standard treatment for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).
Arianna Peyla +6 more
doaj +2 more sources
Peripapillary Retinal Nerve Fibre and Ganglion Cell Layer Changes Following Intravitreal Aflibercept 8 mg Therapy in Neovascular Age-Related Macular Degeneration: A Longitudinal OCT Study [PDF]
Ophthalmology and TherapyIntroduction Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard of care for neovascular age-related macular degeneration (nAMD) and other retinal vascular diseases.
Giulio Volpe +8 more
doaj +2 more sources
Clinical Cancer Research, 2013 Abstract Aflibercept, an intravenously administered anti-VEGF and antiplacental growth factor (PlGF) agent, has recently been approved by the U.S. Food and Drug Administration in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer who have previously ...
Kristen K, Ciombor +2 more
+6 more sources
Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion
Molecules, 2022 Aflibercept is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the treatment of macular edema following central retinal vein occlusion (CRVO).
Lasse Jørgensen Cehofski +9 more
doaj +1 more source
Journal of Ophthalmology, 2021 Background: Proliferative diabetic retinopathy (PDR) can cause a loss of vision due to complications like vitreous hemorrhage and tractional retinal detachment, which require vitrectomy.
Vira S. Ponomarchuk +2 more
doaj +1 more source
Transient Vision Loss Associated with Prefilled Aflibercept Syringes
Ophthalmology Science, 2022 Purpose: To describe cases of significant vision loss after intravitreal aflibercept administration using prefilled syringes (PFS) and to study the relationships among syringe design, injection speed, and injection force.
Daniel J. Lee, MD +4 more
doaj +1 more source
Features of aflibercept plus hyperbaric oxygen therapy for diabetic macular edema
Journal of Ophthalmology, 2022 Background: Diabetes mellitus (DM) is a disease characterized by chronic hyperglycemia and a cascade of pathological vascular alterations leading to diabetic retinopathy (DR) and diabetic macular edema (DME).
V. O. Drozdov, V. M. Sakovych
doaj +1 more source
Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. [PDF]
PLoS ONE, 2015 To compare treatment patterns of intravitreal ranibizumab and aflibercept for the management of neovascular age-related macular degeneration (nAMD) in a real-world setting over the first 12 months of treatment.A proprietary clinical database was used to ...
Alberto Ferreira +5 more
doaj +1 more source
Comparative study between the effect of intravitreal injection of Ranibizumab and Aflibercept on macular oedema secondary to branch retinal vein occlusion [PDF]
Al-Azhar International Medical Journal, 2022 Background: Occlusion of retinal veins is a mutual disorder that affect the retina usually occurs when blood clot obstructs a retinal vein. Aim of the work: To compare the effects of Ranibizumab versus Aflibercept intravitreal injections on macular edema
Ahmed Tawfik +2 more
doaj +1 more source